BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist
Latest Information Update: 01 Jan 2025
Price :
$35 *
At a glance
- Drugs Benralizumab (Primary) ; Beta adrenergic receptor antagonists; Corticosteroids
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 01 Jan 2025 New trial record